Febuxostat-d7

Febuxostat-d7 is deuterium labeled Febuxostat. Febuxostat (TEI 6720) is selective xanthine oxidase inhibitor with a Ki of 0.6 nM[1].

Product Specifications

CAS Number

[1285539-74-3]

Product Name Alternative

TEI 6720-d7; TMX 67-d7

UNSPSC

12352005

Hazard Statement

H301

Target

Isotope-Labeled Compounds; Xanthine Oxidase

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cancer

Purity

99.06

Solubility

10 mM in DMSO

Smiles

OC(C1=C(C)N=C(C2=CC(C#N)=C(C=C2)OCC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])S1)=O

Molecular Formula

C16H9D7N2O3S

Molecular Weight

323.42

Precautions

H301

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Sanchez-Lozada LG, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol, 2008, 108 (4), p69-p78.|[3]Sanchez-Lozada LG, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol, 2008, 294 (4), F710-F718.|[4]Takano Y, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci, 2005, 76 (16), 1835-1847.|[5]Xu X, et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. Card Fail, 2008, 14 (9), 746-753.